Picture of IRADIMED logo

IRMD — IRADIMED News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapHigh Flyer

IRadimed Corp expected to post earnings of 10  cents a share - Earnings Preview

* IRadimed Corp  IRMD.OQ   IRMD.O  is expected to show a fall in
quarterly revenue when it reports results on April 30.
* The Winter Springs, Florida-based company is expected to
report  a 1.3% decrease in revenue to $8.562 million from $8.68
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.​​
​* Refinitiv's mean analyst estimate for IRadimed Corp is for
earnings of 10 cents per share. For the same quarter last year,
the company reported earnings of 18 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months.​
* Wall Street's median 12-month price target for IRadimed Corp
is $29​, about 8% above​ its last closing price of $26.67. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  0.11        0.11       0.07      Missed  -33.3
 Sep. 30 2020  0.10        0.10       0.11      Beat    10
 Jun. 30 2020  0.00        0.00       0.05      Beat    1,100​
 Mar. 31 2020  0.12        0.15       0.18      Beat    20
 Dec.          0.21​       0.21       0.30      Beat    46.3​
 31​ 2019​                                              
 Sep. 30 2019  0.16        0.16       0.23      Beat    48.4​
 Jun. 30 2019  0.15        0.15       0.20      Beat    33.3
 Mar. 31 2019  0.17        0.15       0.13      Missed  -13.3
 This summary was machine generated April 28 at 12:59 GMT.  All
figures in US dollars unless otherwise stated

Recent news on IRADIMED

See all news